Wow, peak global sales of $1.5B annually and the same drug with to treat another rare disease with the readout expected soon. Their share structure is much different than CYDY, but $6.2B market cap compared to $116M simply based on expected market potential seems crazy out of line (even trading on the OTC).

https://www.cnbc.com/video/2019/10/15/reata-s...sults.html